Literature DB >> 21087742

Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions.

Alan J Thompson1, Ahmed T Toosy1, Olga Ciccarelli2.   

Abstract

Management of symptoms in multiple sclerosis (MS) has received little attention compared with disease-modifying treatments. However, the effect of these symptoms on quality of life can be profound. Clinical trials of pharmacological drugs to treat symptoms of MS have often been underpowered and have used inappropriate measures of outcome. Many currently used symptomatic drugs were introduced decades ago, when study quality was considerably below current standards. Therefore, the evidence base on which to make clinical decisions is less than adequate. Interest in pharmacological treatment of symptoms in MS has increased in recent years, and several large randomised controlled trials have been reported. Pharmacological strategies are a core component of the treatment of these symptoms, but it is imperative to remember that a multidisciplinary rehabilitation approach is needed for effective management.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21087742     DOI: 10.1016/S1474-4422(10)70249-0

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  42 in total

Review 1.  Rehabilitation interventions in multiple sclerosis: an overview.

Authors:  Serafin Beer; Fary Khan; Jürg Kesselring
Journal:  J Neurol       Date:  2012-07-08       Impact factor: 4.849

2.  Deletion of mitochondrial anchoring protects dysmyelinating shiverer: implications for progressive MS.

Authors:  Dinesh C Joshi; Chuan-Li Zhang; Tien-Min Lin; Anchal Gusain; Melissa G Harris; Esther Tree; Yewin Yin; Connie Wu; Zu-Hang Sheng; Robert J Dempsey; Zsuzsanna Fabry; Shing Yan Chiu
Journal:  J Neurosci       Date:  2015-04-01       Impact factor: 6.167

3.  Gαq takes centre stage in multiple sclerosis pathogenesis.

Authors:  Eric J Downer
Journal:  Cell Mol Immunol       Date:  2017-02-20       Impact factor: 11.530

Review 4.  Treatment update in multiple sclerosis.

Authors:  Katrina Morris; Con Yiannikas
Journal:  Curr Allergy Asthma Rep       Date:  2012-06       Impact factor: 4.806

5.  Fumarate treatment in progressive forms of multiple sclerosis: first results of a single-center observational study.

Authors:  Katrin Strassburger-Krogias; Gisa Ellrichmann; Christos Krogias; Peter Altmeyer; Andrew Chan; Ralf Gold
Journal:  Ther Adv Neurol Disord       Date:  2014-09       Impact factor: 6.570

Review 6.  Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system.

Authors:  A Salmen; R Gold; A Chan
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

7.  Progressive multiple sclerosis and mood disorders.

Authors:  Lorena Lorefice; G Fenu; G Trincas; M F Moro; J Frau; G C Coghe; E Cocco; M G Marrosu; M G Carta
Journal:  Neurol Sci       Date:  2015-04-22       Impact factor: 3.307

8.  Does long-term partial sodium channel blockade alter disease progression in MS? Evidence from a retrospective study.

Authors:  T J Counihan; J A Duignan; G Gormley; S Saidha; C Dooley; J Newell
Journal:  Ir J Med Sci       Date:  2013-11-28       Impact factor: 1.568

9.  Channelopathy-related SCN10A gene variants predict cerebellar dysfunction in multiple sclerosis.

Authors:  Tina Roostaei; Shokufeh Sadaghiani; Min Tae M Park; Rahil Mashhadi; Aria Nazeri; Sina Noshad; Mohammad Javad Salehi; Maryam Naghibzadeh; Abdorreza Naser Moghadasi; Mahsa Owji; Rozita Doosti; Amir Pejman Hashemi Taheri; Ali Shakouri Rad; Amirreza Azimi; M Mallar Chakravarty; Aristotle N Voineskos; Arash Nazeri; Mohammad Ali Sahraian
Journal:  Neurology       Date:  2016-01-06       Impact factor: 9.910

10.  Eriocalyxin B ameliorates experimental autoimmune encephalomyelitis by suppressing Th1 and Th17 cells.

Authors:  Ying Lu; Bing Chen; Jun-Hong Song; Tao Zhen; Bai-Yan Wang; Xin Li; Ping Liu; Xin Yang; Qun-Ling Zhang; Xiao-Dong Xi; Sheng-Di Chen; Jian-Ping Zuo; Zhu Chen; Sai-Juan Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-23       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.